Genelux Investor Presentation Deck

Systemic Administration + Chemo Generated Encouraging Data Key Trial Takeaways Anti-tumor effect of IV Immunochemotherapy ● ● High and Condensed Dosing (single cycle: bolus infusion on 5 consecutive days) Well tolerated: No DLT or MTD reached Monotherapy: Anti-tumor effects Combination therapy: Virus treatment revitalized tumors to subsequent chemotherapy with prolonged PFS and OS GENELUX Recurrent metastatic cervical cancer with lung mets Case Report (Pt #21A-06) Received 5 consecutive daily i.v. doses Cancer Advent Health Institute Expanded Access Program Transient adverse reactions: fever, nausea, bone pain (Hx arthritis) Stable disease with no tumor size increase 55 53 51 49 47 45 43 41 39 37 35 SLD of nontarget lesions (mm) PD at SD at baseline Wk 24 11/2017 20/2018 /1/2018 10/2018 Chemotherapy after disease progression Partial Response PFS: 70+ Weeks OS: 53.4 Months High-grade pancreatic cancer with lung & liver mets Case Report (Pt.#21A-04) Received 5 consecutive daily i.v. doses Transient adverse reactions: fever, nausea 59% drop of CA19.9 tumor biomarker and Objective Response per RECIST, with PFS of 18 weeks Best change (%) of target lesion sizes from baseline by RECIST Wk 7 0 -5 -10 -15 -20 -25 -30 -35 -40 Partial response Chemotherapy after disease progression 83% drop of CA 19.9 Partial Response by RECIST PFS: 31 wks 20

View entire presentation